Circio Holding ASA - Share Issue/Capital Change 2026

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Reference is made to the stock exchange announcement made by Circio Holding

ASA (the "Company") on 8 April 2026, regarding key information relating to a

potential subsequent offering of up to 7,638,888 new shares in the Company

(the "Subsequent Offering").

The shares in the Company will be traded exclusive of the right to participate

in the subsequent Offering from and including today, 8 April 2026.

Ex. date: 8 April 2026

* * *

This information is published in accordance with the requirements of the

Continuing Obligations in Euronext Rule Book II.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683 34 3811

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

AI assistant